Peer-reviewed veterinary case report
Radiotherapy treatment for dogs with adrenal tumors invading blood
By Dolera, M et al.·Published in The Journal of small animal practice·2016·La Cittadina Fondazione Studi e Ricerche Veterinarie, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Volumetric-modulated arc stereotactic radiotherapy for canine adrenocortical tumours with vascular invasion.
- Species:
- dog
Plain-English summary
A group of nine dogs with adrenal tumors, some of which were secreting cortisol, underwent a specialized type of radiation therapy called hypofractionated stereotactic volumetric-modulated arc radiotherapy. This treatment aimed to shrink the tumors and improve their overall health. After the therapy, the dogs showed a significant reduction in tumor size, and two of the dogs with cortisol-secreting tumors had their hormone levels return to normal. While there were some mild side effects from the treatment, the overall survival time for the dogs was promising, averaging about 1030 days.
People also search for: dog adrenal tumor treatment · cortisol-secreting tumor in dogs · radiation therapy for dog cancer
Abstract
OBJECTIVES: To evaluate the feasibility and efficacy of hypofractionated stereotactic volumetric-modulated arc radiotherapy in treating canine adrenal tumours with vascular invasion. METHODS: A single-arm clinical study was performed. The dogs underwent total body computed tomography, brain and abdomen magnetic resonance imaging and endocrine assay. Adrenal masses were classified as cortisol-secreting adrenal tumour or non-secreting adrenal tumour. Radiotherapy treatments were delivered by hypofractionated stereotactic volumetric-modulated arc radiotherapy via a linear accelerator. The overall survival was estimated by the Kaplan-Meier method. The overall response and radio-toxicity effects were determined. RESULTS: Nine dogs were enrolled. Three dogs were affected by cortisol-secreting adrenal tumours and the remaining dogs had non-secreting adrenal tumours. The prescribed doses ranged from 30 to 45 Gy in three or five consecutive daily fractions. The median overall survival time was 1030 days, and the overall mean reduction of the diameter and volume were ~32 and 30% respectively. The endocrine profile normalised in two dogs with cortisol-secreting adrenal tumours. Radio-toxicities were mild and self-limiting. Seven deaths were recorded during the follow-up period and two dogs were censored. CLINICAL SIGNIFICANCE: Hypofractionated stereotactic volumetric-modulated arc radiotherapy should be considered as a feasible and effective therapeutic option for adrenal tumours with vascular invasion.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27759159/